Pacira BioSciences, Inc. (PCRX) financials · rev $726.4M
Lician Pro · $19.99/mo or $149/yrCompare AAPL vs MSFT
Pacira BioSciences, Inc. (PCRX) rev $726.4M.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $726.4M | $701.0M |
| Cost of Revenue | $149.7M | $170.4M |
| Gross Profit | $576.7M | $530.5M |
| Operating Income | $19.2M | -$73.4M |
| Net Income | $7.03M | -$99.6M |
| EPS (Diluted) | $0.16 | -$2.15 |
| Line | FY2025 | FY2024 |
|---|---|---|
| Total Assets | $1.26B | $1.55B |
| Current Assets | $548.0M | $745.1M |
| Cash & Equivalents | $158.5M | $276.8M |
| Inventory | $152.9M | $125.3M |
| PP&E | $140.7M | $167.2M |
| Total Liabilities | $571.8M | $775.2M |
| Current Liabilities | $120.6M | $309.9M |
| Short-term Debt | N/A | $201.8M |
| Long-term Debt | $372.2M | $383.5M |
| Total Debt | $372.2M† | $585.3M† |
| Shareholders' Equity | $693.1M | $778.3M |
| Retained Earnings | -$199.3M | -$206.4M |
† Total Debt: Derived: short-term debt plus long-term debt (no total debt stored).
| Line | FY2025 | FY2024 |
|---|---|---|
| Operating Cash Flow | $152.0M | $189.4M |
| CapEx | $15.3M | $10.6M |
| Investing Cash Flow | $99.5M | -$83.3M |
| Financing Cash Flow | -$369.6M | $17.4M |
| Net Change in Cash | -$118.2M | $123.5M |
| Free Cash Flow | $136.7M | $178.8M |
FAQ
What is PCRX P/E and revenue?
Pacira BioSciences, Inc. (PCRX) rev $726.4M.
What is PCRX revenue?
Pacira BioSciences, Inc. last cached revenue is $726.4M (FY2025).
Is PCRX profitable?
Pacira BioSciences, Inc. last cached net income is $7.03M (FY2025).
What are PCRX total assets?
Pacira BioSciences, Inc. last cached total assets are $1.26B (FY2025).
What is PCRX free cash flow?
Pacira BioSciences, Inc. last cached free cash flow is $136.7M (FY2025).
Not investment advice. Cached statements, not a live tape.